Saracatinib inhibited αSMA expression in HSCs, thus confirming that activation of HSCs was inhibited, as shown in Figure 4C. Taken together, these data demonstrate that Src inhibition protects against TAA-induced liver fibrosis and the activation of HSCs. The gene discussed is SRC; the disease is Hepatic fibrosis.